Sir, The Ahmed glaucoma valve in refractory glaucoma: experiences in Indian eyes
We read with interest the article by Das et al 1 on their experience on the use of Ahmed valve in the treatment of refractory glaucoma among Indian eyes. The encapsulation rate shown in this paper are indeed very different from our paper published using a similar glaucoma implants in Asian eyes. 2 It was mentioned in the article that no 'hypertensive phase' was observed and the authors attributed this to the continuous egression of aqueous through the dissected scleral flap. Such scleral flap is expected to be quite thin and certainly will not be as deep as what one would expect in nonpenetrating trabeculectomy as the authors made no attempt to create such depth at the time of dissection. If that was the case, egression of fluid through the scleral flap is not likely. If the egression of fluid is from the anterior chamber entry wound, the presence of the scleral flap would make no difference.
Furthermore, if there is still drainage through the scleral flap 4 weeks after the operation, it would be hard to determine whether the control of the IOP is due to the slceral flap draining or the Ahmed valve. appears to be a variation in the surgical technique. The dissection of the scleral flap was the only major surgical modification of the technique that was different from the procedure described in the studies performed previously. 2, 3 Although the scleral dissection was not as deep as it is in nonpenetrating deep sclerectomy (NPDS) in our study, 1 in most cases the flap was between twothirds to three-fourths of the scleral thickness, so as to provide adequate support to the AGV tube. This was the basis of our postulation that egression of aqueous from the scleral flap and bed, 4 as is seen in a trabeculectomy, may have contributed to the blunting of the 'hypertensive' phase. This, however, remains a nonmeasurable compounding factor, which had no adverse outcome on the postoperative behaviour of the patient's intraocular pressure (IOP). Even if we assume that both, the egression of aqueous from the scleral bed and the drainage through the AGV implant, contributed to the reduction in the IOP, the effect was better control of the same in the postoperative period, which was desirable. However, this query provides food for thought for a future randomized prospective comparative study where the implant is inserted under a scleral flap (measured depth) and under a donor corneoscleral graft so as to come to a solution to this clinical dilemma.
Encapsulated blebs were not encountered in our study as a cause of failure. We have mentioned in the article that this could probably be due to a shorter recorded follow-up period or probably a less aggressive tissue healing process in Indian eyes. 1 The latter hypothesis is presumptive and would need substantiation by further randomized trials taking into account the response to surgery in different races. Most of the cases classified as 'failures' in our study were patients with refractory and complicated glaucomas (neovascular, aphakic, postuveitic, congenital, etc) and the cause of failure was due to inadequate control of IOP in spite of maximum medical therapy as defined in our success criteria. 1 Another important difference between the two Asian studies 1,2 on AGV implantation in refractory glaucomas that we thought should be highlighted is that the patient groups in the two studies were different. The most common diagnosis in the study by Lai et al 2 was neovascular glaucoma while that in our study was failed trabeculectomy in primary glaucomas.
